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In this study, a novel phospholipid-based microbubble formulation containing doxorubicin 
and perfluoropropane gas (DLMB) was developed. The DLMBs were prepared by 
mechanical agitation of a phospholipid dispersion in the presence of perfluoropropane (PFP) 
gas. An anionic phospholipid, distearoylphosphatidylglycerol (DSPG) was selected to load 
doxorubicin in the microbubbles by means of electrostatic interaction. The particle size, zeta 
potential, echogenicity and stability of the DLMBs were measured. Drug loading was ≥92%. 
The potential of the DLMBs for use as a theranostic modality were evaluated in tumor 
bearing mice. Gas chromatography analysis of PFP showed significant enhancement of PFP 
retention when doxorubicin was used at concentrations of 10–82% equivalent to DSPG. The 
inhibitory effects on the proliferation of B16BL6 melanoma murine cells in vitro were 
enhanced using a combination of ultrasound (US) irradiation and DLMBs. Moreover, in vivo 
DLMBs in combination with (US) irradiation significantly inhibited the growth of B16BL6 
melanoma tumor in mice. Additionally, US echo imaging showed high contrast enhancement 
of the DLMBs in the tumor vasculature. These results suggest that DLMBs could serve as US 
triggered carriers of doxorubicin as well as tumor imaging agents in cancer therapy. 








1. Introduction  
In cancer therapy, targeted drug delivery to the tumor is a great challenge [1,2]. Many recent 
studies have shown that microbubbles (MBs) serve as a potential modality for both tumor 
therapy and imaging [3]. When systemically administrated, the interaction between the 
perfluoropropane (PFP) gas in MBs and an ultrasound (US) wave result in contrast signal 
enhancement in the blood vessels. However, irradiating MBs with higher pressure amplitude 
US causes cavitations [4,5]. These effects, known as sonoporation, enhance the delivery of 
drugs and nucleic acids into cells for improving therapeutic outcome [6]. Although US is a 
safe, easily performed, and relatively cheap technology, US imaging lacks high resolution 
especially in the case of deep tissues. Therefore, the formulation allows us not only to 
determine MB distribution but also to achieve treatment response at the tumor site in a non-
invasive manner [7, 8]. 
 Doxorubicin is one of the most frequently used anti-cancer agents for a variety of solid 
tumors. Combination of doxorubicin loaded MBs (DLMBs) with US irradiation has been 
found to enhance doxorubicin uptake through US induced cavitations effects [9,10]. 
Regarding the stability of doxorubicin encapsulation into liposomes, the use of anionic 
phospholipids may be suitable for loading via electrostatic interaction [11,12]. For theranostic 
applications concerning the tumor, not only doxorubicin but also PFP gas should be stably 
encapsulated into the formulation. However, MBs lack stability under in vivo conditions as a 
result of gas diffusion and leakage [8,13]. 
For the stable encapsulation of PFP gas into bubble formulations, the selection of lipid is 
an important factor [14,15]. So far, our group has developed positively charged bubble 
liposomes for gene or siRNA delivery in combination with US irradiation [16,17]. 
Additionally, we have developed negatively charged bubble lipopolyplex using 1,2-
distearoyl-sn-glycero-3-phosphatidylglycerol (DSPG) as an anionic lipid for safe and 
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efficient transfection by diminished interaction with erythrocytes [18,19]. Recently, Sax et 
al. have reported that DSPG incorporated bubble (acoustic) liposomes had an enhanced half-
life both in vitro and in vivo [20]. Taking all of these factors into consideration, we expect 
that the use of anionic MBs partly containing DSPG can offer a platform for the 
development of more stable DLMBs with theranostic applications in cancer therapy. 
In the present study, we optimized the conditions required for the preparation of stable 
DLMBs using negatively charged MBs in relation to the encapsulation of doxorubicin and 
PFP gas by means of a simple agitation method. The potential of DLMBs for use in 
theranostics were evaluated under both in vitro and in vivo conditions for cancer therapy and 
US imaging. 
 
2. Materials and methods 
2.1. Phospholipids 
DSPG, 1,2-dipalmitoyl-sn-glycero-3- phosphatidylcholine (DPPC) and PEG2000-DSPE 




The B16BL6 murine melanoma cell line was obtained from the American Type Culture 
Collection (ATCC, Manassas, VA, USA). Cells were cultured in Dulbecco’s modified eagle 
medium Nissui Pharmaceutical Co., Ltd., (Tokyo, Japan) supplemented with 10% fetal 
bovine serum and 100 U/ml penicillin/streptomycin at 37ºC in 5% CO2. 
 
2.3. Animals and tumor models 
6 
 
Female 6-week-old C57BL6 mice were purchased from the Shizouka Agricultural 
Cooperation Association for Laboratory Animals (Shizouka, Japan) and female 6-week-old 
HR1 hairless mice were obtained from Sankyo Laboratory Service Corporation, Inc. (Tokyo, 
Japan). For preparing tumor bearing mice, 1×106 cells in phosphate buffered saline were 
injected subcutaneously into the left flanks of mice with a 26-gauge needle. Experiments 
were initiated when tumors reached 5–10 mm in diameter after 9–14 days. All experiments 
were carried out in accordance with the principles of laboratory animal care in accordance 
with the Principles of the National Institute of Health and Guidelines for Animal Experiments 
of Kyoto University; all experiments were approved by Teikyo University School of 
Medicine Animal Ethics Committee, reference number of approval was: 14-027. 
 
2.4. Doxorubicin liposome and DLMBs preparation  
DPPC, DSPG and PEG2000-DSPE in a 7:2.5:0.5 molar ratio were dissolved in chloroform, 
followed by evaporation of the chloroform in a rotary evaporator at 25°C for 30 min; this was 
followed by further drying under vacuum at room temperature overnight. Ten mg of lipid film 
was hydrated with 3 ml of 5% glucose solution at 65 °C for 60 min under mild agitation. The 
final lipid concentration after hydration was adjusted to 3 mg/ml. The glucose solution also 
contained 2 mg doxorubicin.  For preparing MBs 0.5 ml of liposomes were added to a 5-ml 
sterilized vial. The air in the vial was replaced with PFP gas (Takachiho Chemical Industries 
Co., Tokyo, Japan) and after capping 6 ml of PFP was injected. To obtain the MBs a shaking 
machine (Ultra Mate 2, Victoria, Australia) was used. Temperature was measured after 
agitation using a needle type thermometer (Custom Co., Tokyo, Japan). Perfluoropropane 
content analysis was performed as reported previously [21]. The particle size and zeta potential 
of the liposomes and MBs were determined using a Zetasizer Nano ZS instrument (Malvern 




2.5. Doxorubicin binding efficiency 
To determine the binding efficiency of doxorubicin in DLMBs, a sample consisting of a 
0.5-ml DLMB dispersion  (1.65 mg lipid and 0.33 mg doxorubicin) was centrifuged at 16,000 
g for 2 min. Then the sample was divided to three fractions: a foaming cake at the top which 
contained doxorubicin loaded MBs; a pellet at the bottom, which contained liposomes; and 
in-between a solution containing free doxorubicin. The fractions were collected, and then the 
concentration in each fraction was determined by measuring doxorubicin fluorescence (480 
nm was used as excitation wavelength and doxorubicin signal was detected at 590 nm) 
(FluoroMax4, Horiba, Ltd., Kyoto, Japan).   
 
2.6. In vitro echogenicity 
The DLMBs were injected into a beaker filled with 500 ml of degassed distilled water at 
37°C under magnetic stirring. Ultrasound contrast enhancement was observed using an 
ultrasonography system (Vevo 2100, Visual Sonics, Inc. Toronto, Canada). For additional 
investigations of DLMB destruction by higher energy US burst, an external US probe at an 
intensity of (2 W/cm²) was used. The process of US burst was repeated until most of the 
DLMBs had disappeared.  
 
2.7. In vitro cellular uptake and anti-proliferative assay 
Cellular uptake in vitro was evaluated using a confocal microscopy (Nikon, Tokyo, Japan). 
BL6BL6 cells were grown on cover glasses in 24-well plates (3×105 cells/well). DLMBs were 
added to the medium, containing a doxorubicin concentration of 5 µg/ml. Then a 6-mm US 
probe was immersed into the well and US irradiation was performed for 60 s (2 MHz; 2W/cm²; 
50% Duty; 10 Hz). US acoustic parameters were selected based on the previous DLMBs 
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destructibility experiment. After treatment with DLMBs and US, cells were incubated for only 
15 min to minimize doxorubicin uptake by others mechanisms rather than sonoporation [10]. 
Cells washed with PBS (-) three times and fixed with 4% paraformaldehyde in PBS (-). 
Fluorescence from doxorubicin was detected by using 480 nm as excitation wavelength and 
590 nm for detection. The image was processed using ImageJ software. 
As for anti-proliferative assay, B16BL6 cells were seeded in 6-well plates (3×105 
cells/well) for 24 h; DLMBs/MBs only (0 doxorubicin) were added at different 
concentrations. US was applied for 60 s (2 MHz; 2W/cm²; 50% duty; 10 Hz). After 
treatment, cells were incubated for 5 h and then the medium was changed and the cells were 
incubated again for 24 h. After that the 3-(4,5 sec-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) assay was carried out according to the method as previously 
reported [22]. 
 
2.8. In vivo doxorubicin content in tumors  
DLMBs (70 µg doxorubicin and 330 µg lipid) in 5% glucose were intravenously injected 
at the volume of 200 µl and then immediately tumors were irradiated with US for 60 s. Mice 
were sacrificed 15 min after DLMBs injection and immediately tumors, hearts and livers were 
harvested, weighed and preserved at −80°C until analyzed. Doxorubicin was extracted by 
homogenizing the tumors in a mixture of isopropanol and 1 M HCl aqueous solution (1:1 v/v) 
and incubation for 1 h at 4°C. The samples were then centrifuged at 13,000 g for 15 min, and 
the supernatants were recovered for fluorescence detection (FluoroMax4, Horiba, Ltd., Kyoto, 
Japan). Doxorubicin standard series were prepared in non-treated tumor tissues extracts. 
 
2.9. In vivo tumor inhibition and imaging 
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The first treatment was initiated on the 9th day after tumor transplantation and repeated on 
the 11th and 13th days. Immediately after DLMB administration intravenously, the tumor site 
was irradiated for 60 s with US (2 MHz; 2W/cm²; 50% Duty; 10 Hz). Tumor volume was 
measured every 2–3 days using the formula: (major axis×minor axis2)×0.5. 
HR1 hairless mice (n = 3) inoculated with B16BL6 melanoma were anesthetized and 
placed on an imaging pad; temperature, heart rate and breathing were continuously 
monitored. US imaging was performed as previously described [23]. Briefly, a dedicated 
small animal high spatial-resolution imagining linear transducer (16 MHz; gain, 25 dB; 
dynamic range, 50 dB) (Vevo 2100) was used. Subsequently, DLMBs were injected at a dose 
of 100 µl/mouse (300 µg/ml lipid) and short movies (460 frames) were recorded before and 
at pre-determined time points after injection. For each time point the US contrast power (i.e. 
brightness of the picture) in the tumor was calculated so that the decay of the signal over time 
could be evaluated. Also, to further evaluate the potential of the DLMBs for in vivo imaging 
a maximum intensity persistence (MIP) analysis was made. In this analysis, the highest 
intensities from each frame is accumulated into one picture so that the bubble positions are 
highlighted making it easier to distinguish e.g. blood vessels from the background.  
 
2.10. Statistical analysis 
All data were analyzed as the mean ± SEM. Unpaired, the two tailed distribution Student 
t test was applied and values of P < 0.05 were considered as being statistically significant. 
 
3. Results  
 
3.1. DLMB characteristics  
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The size of the DLMBs was adjusted by means of the mechanical agitation time of the 
shaking machine. Agitation for 60 s was sufficient to produce MBs with an average diameter 
of 1 µm (Table 1). During this procedure, the temperature did not exceed 26.7°C. The 
fluorescence microscope images showed spherical MBs in which the doxorubicin signal was 
observed in the shells (supplementary Fig. 1).PFP gas retention was enhanced by the increase 
of doxorubicin content from 10 to 82% (Fig. 1). The time course study showed that with a 
doxorubicin concentration at 10%, PFP gas leaked even faster than was the case from MBs 
that did not contain doxorubicin. However, at levels of 42% and 82% doxorubicin enhanced 
PFP gas retention was evident for at least 30 min at room temperature relative to both MBs (0 
doxorubicin) and the control (saline with PFP). The loaded dose of doxorubicin in DLMBs 
was adjusted to 497.9 ± 17.4 µg/ml (n = 3), and 92.5% of the total doxorubicin was loaded 
into the DLMBs after total separation from free doxorubicin and pellets (supplementary Fig. 
2). 
The echogenicity of DLMBs was assessed in vitro after injecting the freshly prepared 
DLMBs at 37°C. The brightness mode of ultrasonography showed a high signal from the 
DLMBs even at 10 min (Fig. 2). The acoustic destructibility study involving the DLMBs 
demonstrated that US irradiation from 40 to 60 s caused a significant decrease in the 
ultrasonography video intensity as most of the MBs had been destroyed (Fig. 3). 
 
3.2. In vitro doxorubicin uptake and MTT assay 
In vitro doxorubicin delivery was investigated in B16BL6 cells using confocal scanning 
microscopy. The combination of DLMBs with US irradiation (Fig. 4A) showed higher 
cellular accumulation of doxorubicin after 15 min of treatment as compared with DLMBs in 
the absence of US irradiation (Fig. 4B). The combination of free doxorubicin with US 
irradiation did not achieve high levels of doxorubicin (Fig. 4C).  
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Unloaded MBs in combination with US irradiation resulted in a decrease in tumor cell 
viability by about 32.5%, suggesting that there were cavitation effects associated with 
unloaded MBs in combination with US irradiation. DLMBs used in the absence of US 
irradiation resulted in a decrease in cell viability of approximately 27%. In contrast, cell 
viabilities were significantly reduced after treatment with DLMBs combined with US 
irradiation by 77.9% (1.5 µg /ml doxorubicin) and 84.6% (3.0µg /ml doxorubicin) (Fig. 5).  
 
3.3. Intratumoral content of doxorubicin in tumor bearing mice 
As shown in Fig. 6, the combination of DLMBs with US irradiation significantly 
enhanced the intra-tumoral doxorubicin level (0.536 µg/g tissue) as compared with DLMBs 
without US irradiation (0.100 µg/g) (Fig. 6A). Conversely, the levels of doxorubicin in liver 




3.4. Tumor growth inhibition and body weight change in tumor bearing mice  
By day 27 after tumor transplantation tumor volume in the control group had aggressively 
increased (7156.2 ± 1384 mm3). The tumor volume was slightly inhibited relative to the 
control group (4663.2 ± 454 mm3) in the group of mice treated with DLMBs in the absence 
of US irradiation. In contrast, in the group of mice treated with DLMBs in combination with 
US irradiation there was significant inhibition of tumor volume (2453.9 ± 175 mm3) (Fig. 
7A). Moreover, treatment with DLMBs in combination with US irradiation did not cause any 
significant loss of body weight relative to the control group (Fig. 7B).  
 
3.5. In vivo US imaging  
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After 1 min, the intensity of the contrast enhancement signal was gradually reduced (Fig. 
8A). The images were analyzed by plotting the mean contrast intensity in the tumor area 
against time after DLMB injection (Fig. 8B). We estimated the half-life time of DLMBs to be 
between 2–3 min. Moreover, the maximum intensity persistence (MIP) analysis clearly 
revealed the distribution of DLMB in the tumor vasculature with a distinguished contrast 
signal (Fig. 8C).  
 
4. Discussion  
Many studies have reported on the different methods by which doxorubicin or paclitaxel 
was successfully prepared and tested for tumor therapy in combination with US irradiation 
[10,24,25]. Although most of the previous approaches achieved high therapeutic efficacy in 
vitro and in vivo [9,26], there is a little evidence regarding their potential role in US imaging 
and whether or not the co-encapsulation of PFP and doxorubicin is effective enough for US 
contrast enhancement in addition to enhancing the therapeutic potential of doxorubicin.  
In this study, we examined DLMBs and studied their potential characteristics regarding 
both tumor US imaging and therapy. The size of DLMBs was adjusted by means of agitation; 
initially more agitation lead to smaller MBs and a better distribution, but after 60 s no further 
change was observed in the size distribution and the amount of doxorubicin associated with 
the MBs (data not shown). This result indicates that the majority of doxorubicin-
phospholipids dispersion would from DLMBs with high doxorubicin loading efficiency 
(92.5%). During this procedure, the temperature did not exceed 26.7°C, suggesting that it is a 
mild process which could be beneficial if effective compounds could be included in the 
formulations. The fluorescence images of DLMBs revealed spherical shapes in which 
doxorubicin was bound to the DSPG in the shell through electrostatic interactions between 
the positively charged doxorubicin and the negatively charged MBs (data not shown).  
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Both doxorubicin loading and PFP gas retention are critical factors for successful 
theranostic application. We therefore attempted to investigate a possible relationship between 
PFP gas retention and the amount of doxorubicin intercalated with DSPG in the MBs. Gas 
chromatography was used to quantify the amount of PFP gas in the DLMBs at different 
doxorubicin to DSPG ratios. As shown in Fig. 1, a higher doxorubicin loading enhanced PFP 
gas retention in the DLMBs. These observations led us to believe that not only DSPG 
incorporation in MBs but also the intercalation between DSPG and doxorubicin is an 
important factor regarding stable PFP encapsulation. 
 US burst for a period of 60 s at an intensity of only 2 W/cm2 was sufficient to induce a 
significant decrease in the contrast signal of DLMBs; the presumption was that destruction of 
the DLMBs most likely occurred as a result of bubble cavitation (Fig. 3). The US burst 
caused the bubble destruction may be concluded by comparison between Fig. 3 and Fig. 2. As 
shown in Fig. 2, the same DLMBs monitored with lower energy US but without burst and it 
shows that bubbles remain after 10 min whereas the 2 W/cm2 burst destroyed virtually all 
bubbles in 40 s. Moreover, we showed that doxorubicin uptake in cancer cells was enhanced 
when DLMBs were combined with US irradiation relative to free doxorubicin in combination 
with US irradiation (Fig. 4). Similarly, high in vitro cytotoxicity and effective in vivo delivery 
to the tumor were achieved.  
          It is expected that US irradiation at the tumor site leads to DLMB cavitation and 
doxorubicin release; consequently, the concentration of free doxorubicin may increase in 
tumor but not in the heart and liver. Furthermore, DLMB in combination with US irradiation 
significantly inhibited tumor growth without any reduction in animal body weight. These 
results suggest that DLMBs combined with US irradiation at the tumor site improve 
treatment accuracy and safety with less systemic side effects including cardiotoxicity. 
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As shown in Fig. 3, the imaging potentials of DLMBs were confirmed by US echo 
imaging, which revealed a high contrast enhancement signal in the tumor area in mice after 
DLMB administration. Moreover, we showed that the DLMB contrast signal in the tumor 
vasculature could be clearly distinguished from the surrounding normal tissues. Pysz et al. 
have reported that in vivo the ultrasound imaging signal in tumor bearing mice using MIP 
algorithm could be used to assess tumor vascularity [27]. That is because a correlation 
between the in vivo MIP values with microvessel density analysis was observed. Therefore, 
tumor angiogenesis could be monitored by evaluating the MIP analysis of DLMB distribution 
in the tumor vasculature. A future study following on from the findings of this study will 
evaluate modification of MBs with ligands such peptides or antibodies to enable more 
selective targeting of tumors. 
 
5. Conclusion 
We succeeded in preparing a novel DLMB formulation using a simple mechanical 
agitation method. Doxorubicin bound to DSPG enhanced MB stability relative to unloaded 
MBs. The in vitro experiments revealed that the uptake of doxorubicin was increased by the 
combination of DLMBs and US irradiation as compared with the free form of doxorubicin. In 
mice, doxorubicin distribution in tumor was enhanced when DLMBs were combined with US 
irradiation at the tumor site. Additionally, US echo imaging showed high contrast 
enhancement of the DLMBs in the tumor vasculature. These findings suggest that the 
DLMBs that we prepared achieve US triggered delivery of doxorubicin as well as US 
imaging of tumor for theranostics. These observations could provide valuable information for 
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Fig. 1. Time course study of DLMBs with different doxorubicin concentrations presented as 
percentage equivalent to anionic phospholipids. Mean ± SEM. * P < 0.05 versus the 
corresponding control group (saline with PFP gas). 
 
Fig. 2. DLMBs echogenicity in vitro. (A) US imaging experimental set up. (B) Images of 
DLMBs in brightness mode. 
 
Fig. 3. In vitro DLMBs acoustic destructibility. After the injection of DLMBs US echo 
imaging was performed and then the US destruction beam was applied from the external 
probe at an intensity of 2 W/cm2. (A) Images of DLMB brightness and contrast mode after 
the application of US irradiation. (B) Graph presenting DLMB contrast signal regression after 
six volumes of US irradiation (10 s each). 
 
Fig. 4. Confocal laser microscopy images. (A) DLMBs in combination with US irradiation, 
(B) DLMBs in the absence of US irradiation and (C) free doxorubicin in combination with 
US irradiation (scale bar, 50 µm). Cells were treated with DLMBs and free doxorubicin in 
combination with US irradiation and then incubated for 15 min prior to the analysis.  
 
Fig. 5. Viability of B16BL6 melanoma cells after treatment with DLMBs, unloaded 
microbubbles (0 doxorubicin) and US irradiation alone. Each bar represents the mean ± SEM 
of six experiments. * P < 0.05 versus the corresponding groups with no treatment (N.T.). 
 
Fig. 6. Doxorubicin distribution characteristics after intravenous administration of DLMBs 
with or without US irradiation in tumor bearing mice. The doxorubicin content was measured 
in (A) tumor, (B) heart and (C) liver. Each bar represents the mean ± SEM of five 
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experiments. * P < 0.05 versus the corresponding group that received DLMB in combination 
with US irradiation. 
 
Fig. 7. Tumor inhibition study. (A) Tumor volume in mice. (B) Mouse body weight. Mice 
were divided into three groups: control; DLMBs only; and DLMBs in combination with US 
irradiation. Treatment was performed on the 9th day after tumor transplantation and was 
repeated on the on the 11th and 13th days. Each bar represents the mean ± SEM of 5–6 
experiments. * P < 0.05 
 
Fig. 8. Ultrasound imaging of DLMBs in tumors. (A) Ultrasound images of DLMB signal 
enhancement in both brightness mode (left) and contrast mode (right). (B) Time-intensity 
graph for DLMBs at the tumor site after intravenous administration. (C) MIP analysis images 
of DLMB distribution in the tumor vasculature after intravenous injection.  
 
Supplementary Fig. 1. Fluorescence images based doxorubicin detection. (scale bar of 10 
µm). 
 
Supplementary Fig. 2. DLMBs separation through buoyancy effects after centrifugation. (1) 
DLMBs (2) free doxorubicin (3) pellets of phospholipids aggregates with doxorubicin. 
 
Table 1. Mean particle size and zeta potential of liposomes and microbubbles. n = 3; mean ± 
SEM. 
 




Unloaded liposome  250 ± 1 -0.076 ± 0.02 
DOX loaded liposome 270 ± 6 0.038 ± 0.02 
Unloaded microbubbles (MBs) 1051 ± 4 -0.066 ± 0.04 









































































































































































































































Supplementary Fig. 2 
 
 
 
